MiNK Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
MiNK Therapeutics R&D Spending Growth & History (INKT)
MiNK Therapeutics's r&d spending was $5.8M for fiscal 2025.
View full MiNK Therapeutics company overviewMiNK Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.8M | −$578,588 | −9.13% |
| 2024 | 2024-12-31 | $6.3M | −$9.2M | −59.10% |
| 2023 | 2023-12-31 | $15.5M | −$7.6M | −32.99% |
| 2022 | 2022-12-31 | $23.1M | $9.1M | +65.51% |
| 2021 | 2021-12-31 | $14.0M | $4.5M | +46.87% |
| 2020 | 2020-12-31 | $9.5M | — | — |
MiNK Therapeutics quarterly r&d spending
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.9M | $47,992 | +2.61% |
| Q1 2026 | 2026-03-31 | $1.2M | −$57,812 | −4.58% |
| Q4 2025 | 2025-12-31 | $1.5M | $107,150 | +7.62% |
| Q3 2025 | 2025-09-30 | $1.1M | $602,540 | +111.45% |
| Q2 2025 | 2025-06-30 | $1.8M | −$698 | −0.04% |
| Q1 2025 | 2025-03-31 | $1.3M | −$1.3M | −50.50% |
| Q4 2024 | 2024-12-31 | $1.4M | −$1.9M | −57.53% |
| Q3 2024 | 2024-09-30 | $540,638 | −$2.9M | −84.23% |
| Q2 2024 | 2024-06-30 | $1.8M | −$2.7M | −59.64% |
| Q1 2024 | 2024-03-31 | $2.5M | −$1.6M | −39.20% |
| Q4 2023 | 2023-12-31 | $3.3M | −$2.5M | −43.04% |
| Q3 2023 | 2023-09-30 | $3.4M | −$2.7M | −44.27% |
| Q2 2023 | 2023-06-30 | $4.6M | −$1.3M | −22.42% |
| Q1 2023 | 2023-03-31 | $4.2M | −$1.1M | −20.54% |
| Q4 2022 | 2022-12-31 | $5.8M | $1.9M | +47.14% |
| Q3 2022 | 2022-09-30 | $6.1M | $2.8M | +84.45% |
| Q2 2022 | 2022-06-30 | $5.9M | $2.3M | +63.93% |
| Q1 2022 | 2022-03-31 | $5.3M | $2.2M | +70.36% |
| Q4 2021 | 2021-12-31 | $3.9M | — | — |
| Q3 2021 | 2021-09-30 | $3.3M | $830,184 | +33.16% |
| Q2 2021 | 2021-06-30 | $3.6M | — | — |
| Q1 2021 | 2021-03-31 | $3.1M | — | — |
| Q3 2020 | 2020-09-30 | $2.5M | — | — |
MiNK Therapeutics r&d spending trends
Over the last five fiscal years, MiNK Therapeutics's r&d spending decreased from $9.5M to $5.8M, a change of −$3.8M. The latest reported quarter, Q2 2026, shows $1.9M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review MiNK Therapeutics source filings ↗